The Small Molecule Screening and Synthesis Facility (SMSSF) provides UWCCC members with access to high throughput screening (HTS) instrumentation, chemical and RNAi libraries, synthetic chemistry, computational molecular modeling, virtual screening and expert staff. These are all critical activities for early stage discovery of new anti-cancer drugs. By providing infrastructure and expertise that is not available in individual member laboratories, the SMSSF enables UWCCC members to initiate and implement projects focused on the discovery and development of new anti-cancer agents, as well as the characterization of new drug targets. During the past five years, 50 members from seven of the eight Scientific Programs in the UWCCC have used the SMSSF for their research. The data generated at SMSSF has contributed to over 47 publications from UWCCC members and more than 40 funded grants. During the past five years the SMSSF successfully added three new services: screening of a human genome-wide RNAi library, synthetic chemistry for producing analogs or for scale-up and virtual screening.

Public Health Relevance

New safe and effective drugs are needed to treat human cancers. UWCCC members are able to initiate novel drug discovery projects because the Small Molecule Screening and Synthesis Facility provides access to infrastructure and expertise in drug discovery and to chemical and RNAi libraries that are not available in individual academic laboratories.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
4P30CA014520-42
Application #
9067936
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2016-04-01
Budget End
2017-03-31
Support Year
42
Fiscal Year
2016
Total Cost
Indirect Cost
Name
University of Wisconsin Madison
Department
Type
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Rutter, Carolyn M; Kim, Jane J; Meester, Reinier G S et al. (2018) Effect of Time to Diagnostic Testing for Breast, Cervical, and Colorectal Cancer Screening Abnormalities on Screening Efficacy: A Modeling Study. Cancer Epidemiol Biomarkers Prev 27:158-164
Jadvar, Hossein; Chen, Xiaoyuan; Cai, Weibo et al. (2018) Radiotheranostics in Cancer Diagnosis and Management. Radiology 286:388-400
Denu, Ryan A; Shabbir, Maria; Nihal, Minakshi et al. (2018) Centriole Overduplication is the Predominant Mechanism Leading to Centrosome Amplification in Melanoma. Mol Cancer Res 16:517-527
England, Christopher G; Jiang, Dawei; Ehlerding, Emily B et al. (2018) 89Zr-labeled nivolumab for imaging of T-cell infiltration in a humanized murine model of lung cancer. Eur J Nucl Med Mol Imaging 45:110-120
Ong, Irene M; Gonzalez, Jose G; McIlwain, Sean J et al. (2018) Gut microbiome populations are associated with structure-specific changes in white matter architecture. Transl Psychiatry 8:6
Trentham-Dietz, Amy; Ergun, Mehmet Ali; Alagoz, Oguzhan et al. (2018) Comparative effectiveness of incorporating a hypothetical DCIS prognostic marker into breast cancer screening. Breast Cancer Res Treat 168:229-239
Weiss, Jennifer M; Pandhi, Nancy; Kraft, Sally et al. (2018) Primary care colorectal cancer screening correlates with breast cancer screening: implications for colorectal cancer screening improvement interventions. Clin Transl Gastroenterol 9:148
Bruce, Jordan G; Tucholka, Jennifer L; Steffens, Nicole M et al. (2018) Feasibility of Providing Web-Based Information to Breast Cancer Patients Prior to a Surgical Consult. J Cancer Educ 33:1069-1074
Huynh, Mailee; Pak, Chorom; Markovina, Stephanie et al. (2018) Hyaluronan and proteoglycan link protein 1 (HAPLN1) activates bortezomib-resistant NF-?B activity and increases drug resistance in multiple myeloma. J Biol Chem 293:2452-2465
Wu, Yirong; Fan, Jun; Peissig, Peggy et al. (2018) Quantifying predictive capability of electronic health records for the most harmful breast cancer. Proc SPIE Int Soc Opt Eng 10577:

Showing the most recent 10 out of 1528 publications